

2005 GORDON RESEARCH CONFERENCE ON POLYAMINES

Program



[Sunday June 12, 2005]

Session 1: Physiological and pathophysiological roles

Discussion Leader: Susan Gilmour (Lankenau Medical Research Center)

John Cleveland (St. Jude Children's Research Hospital):

Pathways regulated by ODC in tumorigenesis.

Leonard Johnson (University of Tennessee):

Polyamines and signaling in apoptosis.

Carol Colton (Duke University):

Disruption of polyamine homeostasis in Huntington's disease, a fatal neurodegenerative disease.



[Monday June 13, 2005]

Session 2: Transport

Discussion Leader: Keiko Kashiwagi (Chiba University)

Takeshi Uemura (Chiba University):

Identification of polyamine uptake and excretion.

Mattias Belting (Lund University):

Uptake of polyamines and polybasic peptides via proteoglycans: Implications for tumor growth and gene delivery.

Marie-Pierre Hasne (Oregon Health and Science University):

Polyamine transport in *Leishmania*.

Richard Poulin (Laval University Medical Research Center):

Transport and vesicular sequestration of polyamines in mammalian cells.

Session 3: Mechanisms of action: RNA/translation

Discussion Leader: Anthony J. Micahel (Institute of Food Research)

Eric Westhof (IBMC-CNRS):

Polyamines and aminoglycosides binding to RNA.

Tairo Oshima (Tokyo University of Pharmacy and Life Science):

Polyamines in life around the boiling temperature of water.

Kazuei Igarashi (Chiba University):

Polyamine modulon: the regulatory genes involved in polyamine stimulation of cell growth.



[Tuesday June 14, 2005]

Session 4: Mechanisms of action: RNA processing/eIF-5A

Discussion Leader: Alberto Abbruzzese (Seconda Universita Di Napoli)

Myung Hee Park (National Institutes of Health/NIDCR):

Post-translational modification of hypusine in eukaryotic translation initiation factor 5A (eIF5A).

Sandro Valentini (Sao Paulo State University):

eIF5A and mRNA metabolism.

Annette Kaiser (German University in Cairo):

Modification of eukaryotic initiation factor 5A from *P. vivax* by deoxyhypusine synthase from *P. falciparum*.

<< Poster Presentations I >>

Discussion Leaders: Margaret A. Phillips (University of Texas, Southwestern),
Leena I. Alhonen (University of Kuopio)

Session 5: Mechanisms of action: Translational frameshifting/Antizyme

Discussion Leader: Senya Matsufuji (Jikei University School of Medicine)

Jonathon Dinman (University of Maryland):

[From IREs and viruses: Toward a model of antizyme frameshifting.](#)

Marvin Hackert (University of Texas at Austin):

[Structures of antizyme and antizyme complexes.](#)

Phillip Coffino (University of California, San Francisco):

[ODC to proteasome: Should I stay or should I go?](#)



[Wednesday June 15, 2005]

Session 6: Mechanisms of action: Signaling

Discussion Leader: J. Y. Wang (University of Maryland)

Lisa Shantz (Pennsylvania State University):

[Development of a lethal phenotype on mice with cardiac overexpression of ODC.](#)

Robert Casero (Johns Hopkins School of Medicine):

[Polyamine catabolism: A problem, a target, or both.](#)

Chaim Kahana (Weizmann Institute of Science):

[Signaling ODC degradation by NAD\(P\)H quinone oxidoreductase.](#)

<< Poster Presentation II >>

Discussion Leaders: Margaret A. Phillips (University of Texas, Southwestern),

Leena I. Alhonen (University of Kuopio)

Session 7: Pathophysiological functions: Cancer

Discussion Leader: Diane McClosky (Pennsylvania State College of Medicine)

David Feith (Pennsylvania State University):

[Suppression of upper aerodigestive tract carcinogenesis in p53-deficient mice](#)

by an antizyme transgene.

Frank Berger(University of South Carolina):

Polyamine metabolism and modulation of intestinal tumorigenesis in the ApcMin/+ mouse.

Frank Meyskens (University of California, Irvine):

Clinical prevention trials of DFMO in human cancer: current status and the future?



[Thursday June 16, 2005]

Session 8: Clinical applications

Discussion Leader: Lo Persson (University of Lund)

Karen Doyle (University of California, Davis):

Polyamines and hearing loss - mechanisms of DFMO ototoxicity.

Annette Kuesel (World Health Organization):

Eflornithine: The 'safe' drug for a 'chronic' African disease: T. b. gambiense HAT.

<< Poster Presentation III >>

Discussion Leaders: Margaret A. Phillips (University of Texas, Southwestern),
Leena I. Alhonen (University of Kuopio)

Session 9: Debate: Therapeutic strategies (analogs versus target-directed drugs)

Moderator: Carl W. Proter (Roswell Park Cancer Institute)

Pro alanogs

Pat Woster (Wayne State University), Heather M. Wallace (University of Aberdeen), Larry Marton (Cell Gate, Inc.)

Pro target directed

Ian Blagbrough (University of Bath), Steven Ealick (Cornell Univeristy), Vic

Levin (University of Texas, MD Anderson Cancer Center)
Summary



[Friday June 17, 2005]

Departure